(+/-)-5'-amino-3-methyl-1',3'-dihydro-2H,5H-spiro[imidazolidine-4,2'-indene]-2,5-dione | 765941-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (+/-)-5'-amino-3-methyl-1',3'-dihydro-2H,5H-spiro[imidazolidine-4,2'-indene]-2,5-dione
• 英文别名: 5'-amino-3-methyl-1',3'-dihydro-2H,5H-spiro[imidazolidine-4,2'-indene]-2,5-dione；5'-amino-3-methyl-1',3'-dihydrospiro[imidazolidine-4,2'-indene]-2,5-dione；(+/-)-5'-amino-3-methyl-spiro[imidazolidine-4,2'-indane]-2,5-dione；(+/-)-5'-amino-3-methylspiro[imidazolidine-4,2'-indane]-2,5-dione；5'-amino-3-methyl-spiro[imidazolidine-4,2'-indane]-2,5-dione；(-)-5'-Amino-3-methyl-spiro[imidazolidine-4,2'-indane]-2,5-dione；5-amino-1'-methylspiro[1,3-dihydroindene-2,5'-imidazolidine]-2',4'-dione
• CAS: 765941-72-8；765941-76-2；766536-46-3
• 化学式: C₁₂H₁₃N₃O₂
• 分子量: 231.254
• InChiKey: HNQKTZHNFUTJJW-UHFFFAOYSA-N

物化性质

• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+/-)-5'-amino-3-methyl-1',3'-dihydro-2H,5H-spiro[imidazolidine-4,2'-indene]-2,5-dione 在 硫酸 、 硝酸 作用下， 以 水 为溶剂， 反应 18.0h， 生成 (+/-)-5'-amino-6'-nitro-3-methyl-spiro[imidazolidine-4,2'-indane]-2,5-dione
  参考文献：
  名称：

  WO2007/61694

  摘要：

  公开号：
• 作为产物：
  描述：

  2-(methylamino)indane-2-carbonitrile 在 palladium on activated charcoal 氢气 、 硝酸 、 溶剂黄146 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 生成 (+/-)-5'-amino-3-methyl-1',3'-dihydro-2H,5H-spiro[imidazolidine-4,2'-indene]-2,5-dione
  参考文献：
  名称：

  Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists

  摘要：

  A rapid analogue approach to identification of spirohydantoin-based CGRP antagonists provided novel, low molecular weight leads. Modification of these leads afforded a series of nanomolar benzimidazolinone-based CGRP receptor antagonists. The oral bioavailability of these antagonists was inversely correlated with polar surface area, suggesting that membrane permeability was a key limitation to absorption. Optimization provided compound 12, a potent CGRP receptor antagonist (K-i = 21 nM) with good oral bioavailability in three species. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.045

文献信息

• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110021500A1

  公开（公告）日：2011-01-27

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

  本发明涉及一般式I的新的CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所定义，其互变异构体、同分异构体、对映异构体、立体异构体、水合物、其混合物及其盐以及盐的水合物，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物、它们的用途以及制备它们的方法。
• [EN] ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR CGRP D'ARYL SPIROHYDANTOINE
  申请人：MERCK & CO INC

  公开号：WO2004082678A1

  公开（公告）日：2004-09-30

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及一种对CGRP受体具有拮抗作用的化合物，可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗CGRP参与的这类疾病中使用这些化合物和组合物。
• MONOCYCLIC AMIDE CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20110172205A1

  公开（公告）日：2011-07-14

  Compounds of formula (I): wherein variables B, m, n, J, R 4 , E a , E b , E c , R f , R PG and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式（I）的化合物：其中变量B、m、n、J、R4、Ea、Eb、Ec、Rf、RPG和Y如本文所述，这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗CGRP参与的这类疾病中使用这些化合物和组合物。
• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEURS DE CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2010107605A1

  公开（公告）日：2010-09-23

  Compounds of Formula (I) (wherein variables A1, A2, A3, ring-B, m, n, J, E1, E2, E3, R5, RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.

  公式（I）的化合物（其中变量A1、A2、A3、环B、m、n、J、E1、E2、E3、R5、RPG和Y如本文所述），这些化合物可用作CGRP受体的拮抗剂，并可用于治疗或预防涉及CGRP受体的疾病，如头痛，特别是偏头痛和群集性头痛。该发明还涉及包含公式（I）化合物的制药组合物以及在涉及CGRP受体的疾病的预防或治疗中使用这些化合物和组合物的用途。
• Monocyclic anilide spirohydantoin cgrp receptor antagonists
  申请人：Bell M. Ian

  公开号：US20060148779A1

  公开（公告）日：2006-07-06

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及与CGRP受体拮抗的化合物，这些化合物在治疗或预防CGRP参与的疾病，如头痛、偏头痛和群头痛方面是有用的。本发明还涉及包含这些化合物的药物组合物，以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。